RLYB
Rallybio Corp
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
Rallybio has 7 disclosed suppliers and 2 disclosed customers in SEC filings.
Rallybio Corp
15.51
SentenceWe are obligated to make certain payments under our agreements with Affibody, Sobi, and Kymab Limited ("Sanofi"), including milestone and royalty payments in connection with achievement of certain development and commercial milestones as well as the sale of resulting products under such agreements.
RLYB 10-Kaccession 0001628280-26-018261
SentencePursuant to the PLA, we obtained a license to the Affibody platform technology and a particular ABD, in order to further develop and commercialize certain Affibody ligands, which we are now developing as RLYB116 and RLYB114.
RLYB 10-Kaccession 0001628280-26-018261
SentenceWe acquired all rights to RLYB116 and RLYB114 from Sobi in 2019.
RLYB 10-Kaccession 0001628280-26-018261
SentenceWe acquired rights to RLYB116 from Swedish Orphan Biovitrum AB (Publ) ("Sobi").
RLYB 10-Kaccession 0001628280-26-018261
SentenceUnder the Sales Agreement, TD Cowen will be entitled to compensation equal to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement.
RLYB 10-Kaccession 0001628280-26-018261
SentenceIn July 2025, we entered into a Membership Interest Purchase Agreement (the "ENPP1 Purchase Agreement") with Recursion Exscientia Ventures I, Inc., an indirect wholly-owned subsidiary of Recursion ("Buyer") and Rallybio IPB, LLC, a wholly-owned subsidiary of Rallybio Corporation to sell our interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with HPP, to Buyer (a subsidiary of our joint venture partner Recursion) (the "JV Sale").
Linked news
Expected move
No implied move.